scholarly journals Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

2015 ◽  
Vol 172 (2) ◽  
pp. 208-218 ◽  
Author(s):  
Brian G. Till ◽  
Hongli Li ◽  
Steven H. Bernstein ◽  
Richard I. Fisher ◽  
W. Richard Burack ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Newly Diagnosed ◽  
Mantle Cell

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. TPS223-TPS223 ◽  
Author(s):  
V. A. Morrison ◽  
S. Jung ◽  
J. L. Johnson ◽  
J. Leonard ◽  
B. D. Cheson ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Mantle Cell

scholarly journals Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial

Leukemia ◽  
2015 ◽  
Vol 30 (4) ◽  
pp. 984-987 ◽  
Author(s):  
S Ferrero ◽  
◽  
A Pastore ◽  
C W Scholz ◽  
R Forstpointner ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Mantle Cell

scholarly journals Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial

2014 ◽  
Vol 165 (4) ◽  
pp. 575-578 ◽  
Author(s):  
Michelle Furtado ◽  
Martin J. S. Dyer ◽  
Rod Johnson ◽  
Margie Berrow ◽  
Simon Rule
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Mantle Cell

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

2018 ◽  
Vol 18 (9) ◽  
pp. 569-575.e1 ◽  
Author(s):  
Victor Yazbeck ◽  
Danielle Shafer ◽  
Edward B. Perkins ◽  
Domenico Coppola ◽  
Lubomir Sokol ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Mantle Cell ◽  
Large B Cell

scholarly journals A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

Haematologica ◽  
2012 ◽  
Vol 97 (7) ◽  
pp. 1085-1091 ◽  
Author(s):  
C. Renner ◽  
P. L. Zinzani ◽  
R. Gressin ◽  
D. Klingbiel ◽  
P.-Y. Dietrich ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Multicenter Phase ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document